Maven Securities’s Vivos Therapeutics VVOS Stock Holding History

Maven Securities’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,280	Closed	-$197K	–	1305
2020 Q4	$197K	Buy	+1,280	New	+$234K	0.02%	508

Other funds holding VVOS

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

AIA

Avalon Investment & Advisory Houston, Texas $3.65B AUM 0.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's VVOS Position: Q1 2021 in Review

Maven Securities sold out of Vivos Therapeutics (VVOS) in Q1 2021, closing a stake of 1,280 shares — an estimated $197K sold.

Maven Securities first reported a position in VVOS in Q4 2020 and held it in 1 quarter. The position peaked at $197K in Q4 2020. 18 funds tracked by Wall St. Rank hold VVOS as of Q1 2021.

Maven Securities reported no remaining Vivos Therapeutics position as of Q1 2021 after selling out during the quarter.
Maven Securities sold 1,280 Vivos Therapeutics shares in Q1 2021, an estimated $197K.
Maven Securities first reported a position in Vivos Therapeutics in Q4 2020 and held it in 1 quarter.
Maven Securities's Vivos Therapeutics position peaked at $197K in Q4 2020.
18 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2021.

Based on Maven Securities's 13F filing for Q1 2021, filed 17 May 2021.